Zilucoplan for severe myasthenia gravis flare-ups
Treatments studied
Part of Brain & nervous system, Cancer, Immune system & allergy clinical trials.
This trial tests zilucoplan, a daily injection, to treat severe muscle weakness from myasthenia gravis that requires hospital care. It may help you recover faster and avoid needing a breathing tube.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You are having a severe myasthenia gravis flare-up with swallowing, breathing, or neck weakness that needs hospital care.
- You are at least 18 years old.
- You test positive for AChR antibodies (a marker of myasthenia gravis).
- You have not used a C5 inhibitor (like eculizumab) in the last 3 months, or it did not work for you.
- You have not had rituximab in the last 9 months or started plasma exchange or IVIG in the last 4 weeks.
- You are willing to get a meningococcal vaccine or take antibiotics to prevent infection.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This study tests an investigational drug called GC012F for people with generalized myasthenia gravis (gMG) that hasn't improved with standard treatments. The goal is to see if it can reduce symptoms and improve daily life.
This early study tests a new cell therapy (GC012F) for people with difficult-to-treat generalized myasthenia gravis. The treatment aims to reset the immune system to reduce muscle weakness.
This trial tests an experimental drug (EA5) injected under the skin or into a vein for people with a specific form of myasthenia gravis (caused by AChR antibodies). The goal is to find the safest dose and see how well it may reduce muscle weakness.
This study tests a new daily shot (zilucoplan) for children and teens with generalized myasthenia gravis (gMG), a condition that causes muscle weakness. It aims to see if the drug is safe and helps improve strength and daily functioning.
This study gives an injectable medicine called zilucoplan to children who were part of an earlier trial and could benefit from more treatment. It aims to see if zilucoplan is safe and helpful for young patients with generalized myasthenia gravis.
This trial is for people in France with myasthenia gravis who are already taking zilucoplan. It tracks how well and how safely the medicine works over 3 months in everyday practice.
Hear when a new Generalized Myasthenia Gravis (gMG) trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.